FDA approved the Quadracelﾠ DTaP+IPV ﾠvaccine for use in children age 4-6 years
On Mar. 24, 2015, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Quadracel, a newﾠcombinationﾠDTaP+IPVﾠ vaccine for use in children age 4 6 years.
Quadracel was the second DTaP-IPV vaccine to be licensed for use among children aged 4 through 6 years in the U.S.
Tags:
Source: U.S. Centers for Disease Control and Prevention
Credit:
